1-5 of 5
Lisa Zimmer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

Martin Schuler, Lisa Zimmer, Kevin B. Kim, Jeffrey A. Sosman, Paolo A. Ascierto, Michael A. Postow, Filip Y.F.L. De Vos, Carla M.L. van Herpen, Matteo S. Carlino, Douglas B. Johnson, Carola Berking, Micaela B. Reddy, Allison S. Harney, Jordan D. Berlin, Rodabe N. Amaria
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (14): 3002–3010.
https://doi.org/10.1158/1078-0432.CCR-21-3872
Published: 15 July 2022
View article titled, Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <em>NRAS</em>-mutant Melanoma
Open the PDF for Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <em>NRAS</em>-mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

Jan C. Brase, Robert F.H. Walter, Alexander Savchenko, Daniel Gusenleitner, James Garrett, Tobias Schimming, Renata Varaljai, Deborah Castelletti, Ju Kim, Naveen Dakappagari, Ken Schultz, Caroline Robert, Georgina V. Long, Paul D. Nathan, Antoni Ribas, Keith T. Flaherty, Boguslawa Karaszewska, Jacob Schachter, Antje Sucker, Kurt W. Schmid, Lisa Zimmer, Elisabeth Livingstone, Eduard Gasal, Dirk Schadendorf, Alexander Roesch
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4500–4510.
https://doi.org/10.1158/1078-0432.CCR-20-3586
Published: 15 August 2021
View article titled, Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Open the PDF for Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib in another window
Includes: Supplementary data
Journal Articles

Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)

Aljosja Rogiers, Carlo Tondini, Joe M. Grimes, Megan H. Trager, Sharon Nahm, Leyre Zubiri, Neha Papneja, Arielle Elkrief, Jessica Borgers, April Rose, Johanna Mangana, Michael Erdmann, Ines Pires da Silva, Christian Posch, Axel Hauschild, Lisa Zimmer, Paola Queirolo, Caroline Robert, Karijn Suijkerbuijk, Paolo A. Ascierto, Paul Lorigan, Richard Carvajal, Osama E Rahma, Mario Mandala, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): S02-01.
https://doi.org/10.1158/1557-3265.COVID-19-S02-01
Published: 15 September 2020
View article titled, Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)
Journal Articles

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

Lisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, Veronique Dieras, Jan H.M. Schellens, Jean-Philippe Spano, Mark R. Middleton, Emiliano Calvo, Luiz Paz-Ares, James Larkin, Simon Pacey, Miro Venturi, Françoise Kraeber-Bodéré, Jean J.L. Tessier, Wilfried Ernst Erich Eberhardt, Michel Paques, Ernesto Guarin, Valerie Meresse, Jean-Charles Soria
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (16): 4251–4261.
https://doi.org/10.1158/1078-0432.CCR-14-0341
Published: 13 August 2014
View article titled, Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <em>RAS–RAF</em> Mutations
Open the PDF for Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <em>RAS–RAF</em> Mutations in another window
Includes: Supplementary data
Journal Articles

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response

Klaus G. Griewank, Henrike Westekemper, Bastian Schilling, Elisabeth Livingstone, Tobias Schimming, Antje Sucker, Uwe Hillen, Klaus-Peter Steuhl, Lisa Zimmer, Dirk Schadendorf
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (22): 6331–6332.
https://doi.org/10.1158/1078-0432.CCR-13-2368
Published: 14 November 2013
View article titled, Conjunctival Melanomas Harbor <em>BRAF</em> and <em>NRAS</em> Mutations—Response
Open the PDF for Conjunctival Melanomas Harbor <em>BRAF</em> and <em>NRAS</em> Mutations—Response in another window